RecruitingEarly Phase 1

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

United States90 participantsStarted 2023-11-01

Plain-language summary

This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. For AS: surgical history of intrauterine trauma/infection, hypo/amenorrhea, intra-uterine adhesions
✓. for AE: US documentation of persistent, \<6mm endometrial thickness
✓. for RIF: failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles in a woman under 40 years and currently being treated at Yale Fertility Clinic

What they're measuring

Change in endometrial thickness and implantation rates following treatment with Plerixafor at 6 month intervals up to 24 months, compared to controls

Timeframe: Every 6 months from baseline up to 24 months

Trial details

NCT IDNCT05343572

SponsorHugh Taylor

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Hugh S Taylor, MD

(203)-785-6949 hugh.taylor@yale.edu

View on ClinicalTrials.gov More Asherman Syndrome trials